Natural benzodiazepines and hepatic encephalopathy

Seminars in Liver Disease

Volumn 16, Issue 3, 1996, Pages 255-264

  Mullen, Kevin D ^a   Jones, E Anthony ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; FLUMAZENIL; SARMAZENIL;

HEPATIC ENCEPHALOPATHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; LIVER FAILURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0030466368     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007238     Document Type: Review

References (82)

1. Anderson B: A proposed theory for the encephalopathies of Reye's syndrome and hepatic encephalopathy. Med Hypotheses 15:415-20. 1984.
2. Bansky G, Meier PJ, Ziegler WH, et al: Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet i:1324-5, 1985. (Letter)
3. Mullen KD. Martin JV, Mendelson WB, et al: Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet i:457-9. 1988.
4. Jones EA: Benzodiazepine receptor ligands and hepatic encephalopathy. Further unfolding of the GABA story. Hepatology 14.1286-1290. 1991.
5. Jones EA, Yurdaydin C. Basile AS: The GABA hypothesisstate of the art. In. Felipo V. Grisolia S (eds): Hepatic Encephalopathy, Hyperammonemia, and Ammonia Toxicity. Plenum Press. New York. Adv Exp Med Biol 368:89-1012; 1994.
6. Schafer DF, Pappas SC, Brody LE, et al: Visual evoked potentials in a rabbit model of hepatic encephalopathy. I. Sequential changes and comparisons with drug-induced comas. Gastroenterology 86:540-5, 1984.
7. Jones DB, Mullen KD, Roessle M, et al: Hepatic encephalopathy: application of visual evoked responses to test hypotheses of its pathogenesis in rats. J Hepatol 4:118-26, 1987.
8. Basile AS, Jones EA, Skolnick P: The pathogenesis and treatment of hepatic encephalopathy; evidence for the involvement of benzodiazepine receptor ligands. Pharm Rev 43:27-71, 1991.
9. Jones EA, Ferenci P: Hepatic encephalopathy and GABAergic neurotransmission. In: Conn HO, Bircher J (eds): Hepatic Encephalopathy: Management with Nonabsorbed Carbohydrates and Other Innovative Therapies. Bloomington, IL, Medi-Ed Press, pp 75-100.
10. A) receptor complex and hepatic encephalopathy. Some recent advances. Ann Intern Med 110:532-46, 1989.
11. Jones EA, Skolnick P: Benzodiazepine receptor ligands and the syndrome of hepatic encephalopathy. In: Popper H, Schaffner F (eds): Progress in Liver Diseases. Volume IX. Philadelphia, WB Saunders, 1990, pp 345-70.
12. Baraldi M, Zeneroli ML, Ventura E, et al: Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist. Clin Sci 67:167-75, 1984.
13. Bassett ML, Mullen KD, Skolnick P, Jones EA: Amelioration of hepatic encephalopathy by pharmacological antagonism of the GABA, benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 93:1069-77, 1987.
14. Scollo-Lavizzari G, Steinmann E: Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet i:1324; 1985. (Letter)
15. Bassett ML, Mullen DK, Scholz B, et al: Increased brain uptake of gamma-aminobutyric acid in a rabbit model of hepatic encephalopathy. Gastroenterology 98:747-57, 1990.
16. Albrecht J, Rafalowska U: Enhanced potassium-stimulated gamma-aminobutyric acid release by astrocytes derived from rats with early hepatic encephalopathy. J Neurochem 49:9-11, 1987.
17. Wysmyk-Cybula U, Dabrowiecki Z, Albrecht J: Changes in the metabolism and binding of GABA in the rat brain in thioacetamide-induced hepatogenic encephalopathy. Biomed Biochim Acta 45:413-19, 1986.
18. Albrecht J, Hilgier W, Rafalowska U: Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamideinduced hepatic encephalopathy: an adaptive response? J Neuroscience Res 25:125-30, 1990.
19. Wysmyk U, Oja SS, Saransaari P, Albrecht J: Enhanced GABA release in cerebral cortical slices from rats with thioacetamideinduced hepatic encephalopathy. Neurochem Res 17:1187-90, 1992.
20. A binding sites in the cerebral cortex of rats with acute hepatic encephalopathy. Brain Res 629:355-7, 1993.
21. A receptor shows a ligand-gated receptor super-family. Nature 328:221-7, 1987.
22. Skolnick P, Paul SM: The benzodiazepine/GABA receptor chloride channel complex. ISI Atlas Sci: Pharmacol 2:19-22, 1988.
23. A receptors. FASEB J 4:1469-80, 1990.
24. Study RE, Barker JL: Diazepam and ( - )-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurones. Proc Natl Acad Sci USA 78:7180-4, 1981.
25. Haefely W, Kyburaz E, Gerecke M, Mohler H: Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists. Adv Drug Res 14:165-322, 1985.
26. Haefely WE, Martin JR, Richards JG, Schoch P: The multiplicity of actions of benzodiazepine receptor ligands. Can J Psychiatry 38(suppl 4):S102, 1993.
27. A receptor channel: a mechanism for interaction with a multitude of central ner-vous system functions. In: Mohler H, Da Prada M (eds): The Challenge of Neuropharmacology. A Tribute to the Memory of Willy Haefely. Basel, Editiones Roche, 1994, pp 15-39.
28. Jones EA, Basile AS, Mullen KD, Gammal SH: Flumazenil: Potential implications for hepatic encephalopathy. Pharmacol Ther 45:331-43, 1990.
29. Gardner CR. Pharmacological profiles in vivo of benzodiazepine receptor Uganda Drug Devel Res 12:1-28, 1988.
30. Bakti G, Fisch HU, Karlaganis G, et al: Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 7:629-38, 1987.
31. Basile AS, Gammal SH, Mullen KD, et al: Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. J Neurosci 8:2414-21, 1988.
32. A receptor in hepatic encephalopathy. Autoradiographic evidence for the presence of elevated levels of a benzodiazepine receptor ligand. Neuropsychopharmacol 3:61-71, 1990.
33. Mohler H, Richards JG: Agonist and antagonist benzodiazepine receptor interactions in vitro. Nature 294:763-5, 1981
34. Braestrup C, Schmiechen R, Neef G, et al: Interaction of convulsive ligands with benzodiazepine receptors. Science 216:1241-3, 1982.
35. Skolnick P, Schwen MM, Williams ER, et al: An in vitro binding assay which differentiates benzodiazepine "agonists" and "antagonists." Eur J Pharmacol 78:133-6, 1982.
36. Basile AS, Panell L, Jaouni T, et al: Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proc Natl Acad Sci USA 87:5263-7, 1990.
37. Basile AS: The contribution of endogenous benzodiazepine receptor ligands to the pathogenesis of hepatic encephalopathy. Synapse 7:141-50, 1991.
38. Mullen KD, Martin JV, Mendelson WB, et al: Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy. Metabolic Brain Dis 4:253-60, 1989.
39. Areceptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous benzodiazepine receptor ligand. J Neurochem 53:1057-63, 1989.
40. Olasmaa M, Rothstein JD, Guidotti A, et al: Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J Neurochem 55:2015-23, 1990.
41. Widler P, Fisch HU, Schoch P, et al: Increased benzodiazepinelike activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat. Hepatology 18:1459-64, 1993.
42. Basile AS, Jones EA: The involvement of benzodiazepine receptor ligands in hepatic encephalopathy. Hepatology 20:541-2, 1994.
43. Olasmaa M, Guidotti A, Costa E, et al: Endogenous benzodiazepines in hepatic encephalopathy. Lancet i:491-2, 1989.
44. Mullen KD, Szauter KM, Kaminsky-Russ K: "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 336:81-3, 1990.
45. Basile AS, Hughes RD, Harrison PM, et al: Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 325:473-8, 1991.
46. Mullen KD: Benzodiazepine compounds and hepatic encephalopathy. N Engl J Med 325:509-11, 1991.
47. Yurdaydin C, Gu Z-Q, Nowak G, et al: Benzo-diazepine receptor ligands are elevated in an animal model of hepatic encephalopathy: relationship between brain concentration and severity of encephalopathy. J Pharm Exp Ther 265:565-71, 1993.
48. Basile AS, Harrison PM, Hughes RD, et al: Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 19:112-21, 1994.
49. Rothstein JD, McKhann G, Guarneri P, et al: Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy. Ann Neurol 26:57-62, 1989.
50. Mullen KD, Kaminsky-Russ K: Pathogenesis of hepatic encephalopathy: Potential future approaches. Digest Dis 14(Suppl l):20-29, 1996.
51. Shoyab M, Gentry L. Marquardt H, Todaro G: Isolation and characterization of a putative endogenous benzodiazepinoid (endozepine) from bovine and human brain. J Biol Chem 261:1168-73, 1986.
52. Matquardt H, Todaro G, Shoyab M: Complete amino acid sequences of bovine and human endozepines. J Biol Chem 262:9227-31, 1986.
53. Gray PW: Molecular biology of diazepam binding inhibitor. Neuropharmacology 26:863-6, 1987.
54. Mullen KD, Szauter KM, Kaminsky-Russ K, et al: Detection and characterization of endogenous benzodiazepine activity in both animal models and humans with hepatic encephalopathy. In: Butterworth RF, Layrargues GP (eds): Hepatic Encephalopathy: Pathophysiology and Treatment. Clifton, NJ, Humana Press, 1989. pp. 287-94.
55. DeBlas AL, Park D, Friedrich P: Endogenous benzodiazepinelike molecules in the human, rat and bovine brains studied with a monoclonal antibody to benzodiazepines. Brain Res 413:275-84. 1987.
56. Medina JH, Pena C, Piva M, et al: Presence of benzodiazepinelike molecules in mammalian brain and milk. Biochem Biophys Res Commun 152:534-9, 1988.
57. Unseld E, Krishna DR, Fischer C, Klotz U: Detection of desmethyldiazepam and diazepam in brain of different species and plants. Biochem Pharmacol 38:2473-8, 1989.
58. Sangameswaran L, Fales HM, Friedrich P, DeBlas A: Purification of a benzodiazepine from bovine brain and detection of benzodiazepine-like immunoreactivity in human brain. Proc Natl Acad Sci USA 83:9236-40, 1986.
59. Wildmann J, Niemann J, Matthaei H: Endogenous benzodiazepine receptor agonist in human and mammalian plasma. J Neural Transm 66:151-60, 1986.
60. Wildmann J, Ranalder U: Presence of lorazepam in the blood plasma of drug free rats. Life Sci 43:1257-60 1988.
61. Unseld E, Fischer C, Rothemund E, Klotz U: Occurrence of "natural" diazepam in human brain. Biochem Pharmacol 39:210-12, 1990.
62. Wildmann J, Vetter W, Ranalder UB, et al: Occurrence of pharmacologically active benzodiazepines in trace amounts in wheat and potato. Biochem Pharmacol 37:3549-59, 1988.
63. Wildmann J: Increase of neural benzodiazepines in wheat and potato during germination. Biochem Biophys Res Commun 157.1436-43,1988.
64. Luckner M: Secondary Metabolism in Microorganisms, Plants and Animais. Berlin, Springer, 1984, p. 274.
65. Yurdaydin C, Engler H, Walsh TJ, et al: Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 679:42-8, 1995.
66. Pomier-Layrargues G, Giguere J-F, Lavoie J, et al: Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate and severe liver dysfunction. Hepatology 10:969-72. 1989.
67. Gammal SH, Basile AS, Geller D, et al: Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology 11:371-8, 1990.
68. van der Rijt CCD, de Knegt RJ, Schalm SW, et al: Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit. Metabolic Brain Dis 5:131-41, 1990.
69. Bosman DK, van der Buijs CACG, de Haan JG, et al: The effects of benzodiazepine receptor antagonists and partial inverse agonists in acute hepatic encephalopathy in the rat. Gastroenterology 101:772-81, 1991.
70. A-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 14:963-8, 1991.
71. Puspok A, Hemeth A, Steindl P, Ferenci P: Hepatic encephalopathy in rats with thioacetamide-induced acute liver failure is not mediated by endogenous benzodiazepines. Gastroenterology 105:851-7, 1993.
72. Mullen KD, Basile AS: Benzodiazepine receptor antagonists and hepatic encephalopathy: where do we stand? Gastroenterology 105:937-40, 1993.
73. Blitzer BL, Waggoner JG, Jones EA, et al: A model of fulminant hepatic failure in the rabbit. Gastroenterology 74:664-71, 1978.
74. Mullen KD, Schafer DF, Cuchi P, et al: Evaluation of the suitability of galactosamine-induced fulminant hepatic failure as a model of hepatic encephalopathy in the rat and rabbit. In: Soeters PB, Wilson JMP, Meijer AJ, Holm E (eds): Recent Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam, Elsevier, 1988, pp 205-12.
75. Grimm G, Ferenci P, Katzenschlager R, et al: Improvement in hepatic encephalopathy treated with flumazenil. Lancet ii: 1392-4, 1988.
76. Bansky G, Meier PJ, Riederer E, et al: Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 97:744-50, 1989.
77. Burke DA, Mitchell KW, Al Mardini H, et al: Reversal of hepatic coma with flumazenil with improvement in visual evoked potentials. Lancet i:505-506, 1988.
78. Savic I, Widen L, Stone-Elander S: Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 337:133-7, 1991.
79. Googay R, Hayes PC, Bzeizi K, O'Carroll RE: Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy. Psychopharmacology 119:295-8, 1995.
80. Ferenci P, Grimm G, Gangl A: Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 96:240-3, 1989.
81. Jones EA, Yurdaydin C, Basile AS: Benzodiazepine antagonists and the management of hepatic encephalopathy. In: Capocaccia L, Merli M, Riggio O (eds): Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL, CRC Press, 1995, pp 549-63.
82. Schafer DF: Hepatic coma: studies on the target organ. Gastroenterology 93:1131-4, 1987.